Compare Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Global ex-US Real Estate Index Fd ETF vs Zimmer Biomet Holdings Inc — how do they compare? Vanguard Global ex-US Real Estate Index Fd ETF trades at $42.15 (market cap $3.80B), while Zimmer Biomet Holdings Inc trades at $89.14 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 4.5× Vanguard Global ex-US Real Estate Index Fd ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Global ex-US Real Estate Index Fd ETF for 95 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| VNQI | ZBH | |
|---|---|---|
Market Cap | $3.80B | $16.95B |
Volume | 277,049 | 2,505,240 |
52-Week High | $50.76 | $103.98 |
52-Week Low | $41.81 | $79.58 |
Typical Hold Time | 95 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VNQI trades at $42.15, up 0.81% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF focuses on international real estate, offering diversification and a higher dividend yield than some peers, but key financial ratios are not disclosed in the provided data. Recent news highlights a significant drop in short interest and comparisons with competing real estate ETFs.
The outlook remains cautious due to weak technical momentum and global real estate market uncertainties. Opportunities include international diversification and income from dividends, but risks involve currency fluctuations, economic cycles abroad, and underperformance versus U.S. real estate. Investors should weigh the bearish technicals against long-term diversification benefits.
Zimmer Biomet (ZBH) trades at $89.14, up 0.73% today, with a bearish technical signal but strong recent earnings beats. The stock shows robust fundamentals with a 69.87% gross margin and 2025 revenue of $8.23B, though net income margin has declined from 2023 peaks. Analyst consensus is a Buy with a $103.11 target, indicating potential upside, supported by a steady dividend and institutional accumulation.
The outlook is mixed: valuation metrics like a P/E of 21.57 appear reasonable, and earnings momentum is positive, but technical weakness and rising debt-to-asset ratios pose risks. Investment appeal hinges on execution of commercial transformations and procedure volume recovery, balancing growth prospects against competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
